NASDAQ:CEMI

Chembio Diagnostics Competitors

$2.84
+0.05 (+1.79 %)
(As of 07/30/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.72
$3.08
50-Day Range
$2.06
$5.34
52-Week Range
$2.06
$8.75
Volume6.41 million shs
Average Volume30.31 million shs
Market Capitalization$57.51 million
P/E RatioN/A
Dividend YieldN/A
Beta1.85

Chembio Diagnostics (NASDAQ:CEMI) Vs. SLGL, BLU, KALA, CTIC, PIRS, and TRVN

Should you be buying CEMI stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Chembio Diagnostics, including Sol-Gel Technologies (SLGL), BELLUS Health (BLU), Kala Pharmaceuticals (KALA), CTI BioPharma (CTIC), Pieris Pharmaceuticals (PIRS), and Trevena (TRVN).

Chembio Diagnostics (NASDAQ:CEMI) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares Chembio Diagnostics and Sol-Gel Technologies' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chembio Diagnostics$32.47 million1.77$-25,520,000.00($1.28)-2.22
Sol-Gel Technologies$8.77 million26.11$-29,290,000.00($1.30)-8.64

Chembio Diagnostics has higher revenue and earnings than Sol-Gel Technologies. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than Chembio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Chembio Diagnostics has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, Sol-Gel Technologies has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for Chembio Diagnostics and Sol-Gel Technologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chembio Diagnostics01102.50
Sol-Gel Technologies00303.00

Chembio Diagnostics currently has a consensus target price of $9.00, suggesting a potential upside of 216.90%. Sol-Gel Technologies has a consensus target price of $19.00, suggesting a potential upside of 69.19%. Given Chembio Diagnostics' higher probable upside, analysts clearly believe Chembio Diagnostics is more favorable than Sol-Gel Technologies.

Profitability

This table compares Chembio Diagnostics and Sol-Gel Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chembio Diagnostics-72.88%-79.63%-36.46%
Sol-Gel TechnologiesN/A-56.28%-48.92%

Institutional & Insider Ownership

34.0% of Chembio Diagnostics shares are held by institutional investors. Comparatively, 28.3% of Sol-Gel Technologies shares are held by institutional investors. 3.8% of Chembio Diagnostics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Chembio Diagnostics beats Sol-Gel Technologies on 9 of the 14 factors compared between the two stocks.

Chembio Diagnostics (NASDAQ:CEMI) and BELLUS Health (NASDAQ:BLU) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, dividends, profitability, valuation, institutional ownership and earnings.

Earnings & Valuation

This table compares Chembio Diagnostics and BELLUS Health's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chembio Diagnostics$32.47 million1.77$-25,520,000.00($1.28)-2.22
BELLUS Health$10,000.0022,718.60$-31,760,000.00($0.54)-5.37

Chembio Diagnostics has higher revenue and earnings than BELLUS Health. BELLUS Health is trading at a lower price-to-earnings ratio than Chembio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Chembio Diagnostics has a beta of 1.85, suggesting that its stock price is 85% more volatile than the S&P 500. Comparatively, BELLUS Health has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500.

Institutional & Insider Ownership

34.0% of Chembio Diagnostics shares are held by institutional investors. Comparatively, 60.6% of BELLUS Health shares are held by institutional investors. 3.8% of Chembio Diagnostics shares are held by company insiders. Comparatively, 24.2% of BELLUS Health shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Chembio Diagnostics and BELLUS Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chembio Diagnostics-72.88%-79.63%-36.46%
BELLUS Health-249,173.31%-28.96%-27.63%

Analyst Recommendations

This is a summary of current ratings and target prices for Chembio Diagnostics and BELLUS Health, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chembio Diagnostics01102.50
BELLUS Health00603.00

Chembio Diagnostics currently has a consensus target price of $9.00, suggesting a potential upside of 216.90%. BELLUS Health has a consensus target price of $9.20, suggesting a potential upside of 217.24%. Given BELLUS Health's stronger consensus rating and higher probable upside, analysts clearly believe BELLUS Health is more favorable than Chembio Diagnostics.

Summary

BELLUS Health beats Chembio Diagnostics on 9 of the 14 factors compared between the two stocks.

Chembio Diagnostics (NASDAQ:CEMI) and Kala Pharmaceuticals (NASDAQ:KALA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Valuation & Earnings

This table compares Chembio Diagnostics and Kala Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chembio Diagnostics$32.47 million1.77$-25,520,000.00($1.28)-2.22
Kala Pharmaceuticals$6.36 million35.06$-104,330,000.00($1.99)-1.73

Chembio Diagnostics has higher revenue and earnings than Kala Pharmaceuticals. Chembio Diagnostics is trading at a lower price-to-earnings ratio than Kala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Chembio Diagnostics has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, Kala Pharmaceuticals has a beta of 0.44, suggesting that its share price is 56% less volatile than the S&P 500.

Institutional and Insider Ownership

34.0% of Chembio Diagnostics shares are held by institutional investors. Comparatively, 56.9% of Kala Pharmaceuticals shares are held by institutional investors. 3.8% of Chembio Diagnostics shares are held by company insiders. Comparatively, 34.2% of Kala Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Chembio Diagnostics and Kala Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chembio Diagnostics-72.88%-79.63%-36.46%
Kala Pharmaceuticals-1,318.03%-101.43%-48.93%

Analyst Ratings

This is a summary of current ratings and recommmendations for Chembio Diagnostics and Kala Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chembio Diagnostics01102.50
Kala Pharmaceuticals01302.75

Chembio Diagnostics presently has a consensus target price of $9.00, suggesting a potential upside of 216.90%. Kala Pharmaceuticals has a consensus target price of $22.00, suggesting a potential upside of 537.68%. Given Kala Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Kala Pharmaceuticals is more favorable than Chembio Diagnostics.

Chembio Diagnostics (NASDAQ:CEMI) and CTI BioPharma (NASDAQ:CTIC) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Valuation & Earnings

This table compares Chembio Diagnostics and CTI BioPharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chembio Diagnostics$32.47 million1.77$-25,520,000.00($1.28)-2.22
CTI BioPharma$3.35 million65.99$-52,450,000.00($0.74)-3.20

Chembio Diagnostics has higher revenue and earnings than CTI BioPharma. CTI BioPharma is trading at a lower price-to-earnings ratio than Chembio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Chembio Diagnostics has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, CTI BioPharma has a beta of 0.7, suggesting that its share price is 30% less volatile than the S&P 500.

Institutional and Insider Ownership

34.0% of Chembio Diagnostics shares are held by institutional investors. Comparatively, 46.5% of CTI BioPharma shares are held by institutional investors. 3.8% of Chembio Diagnostics shares are held by company insiders. Comparatively, 6.9% of CTI BioPharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Chembio Diagnostics and CTI BioPharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chembio Diagnostics-72.88%-79.63%-36.46%
CTI BioPharmaN/A-135.08%-95.67%

Analyst Ratings

This is a summary of current ratings and recommmendations for Chembio Diagnostics and CTI BioPharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chembio Diagnostics01102.50
CTI BioPharma00503.00

Chembio Diagnostics presently has a consensus target price of $9.00, suggesting a potential upside of 216.90%. CTI BioPharma has a consensus target price of $7.50, suggesting a potential upside of 216.46%. Given Chembio Diagnostics' higher probable upside, equities research analysts plainly believe Chembio Diagnostics is more favorable than CTI BioPharma.

Chembio Diagnostics (NASDAQ:CEMI) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Valuation & Earnings

This table compares Chembio Diagnostics and Pieris Pharmaceuticals' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chembio Diagnostics$32.47 million1.77$-25,520,000.00($1.28)-2.22
Pieris Pharmaceuticals$29.32 million7.51$-37,230,000.00($0.68)-5.12

Chembio Diagnostics has higher revenue and earnings than Pieris Pharmaceuticals. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than Chembio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Chembio Diagnostics has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.

Institutional and Insider Ownership

34.0% of Chembio Diagnostics shares are held by institutional investors. Comparatively, 50.7% of Pieris Pharmaceuticals shares are held by institutional investors. 3.8% of Chembio Diagnostics shares are held by company insiders. Comparatively, 5.8% of Pieris Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Chembio Diagnostics and Pieris Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chembio Diagnostics-72.88%-79.63%-36.46%
Pieris Pharmaceuticals-119.28%-94.73%-33.29%

Analyst Ratings

This is a summary of current ratings and recommmendations for Chembio Diagnostics and Pieris Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chembio Diagnostics01102.50
Pieris Pharmaceuticals00303.00

Chembio Diagnostics presently has a consensus target price of $9.00, suggesting a potential upside of 216.90%. Pieris Pharmaceuticals has a consensus target price of $8.50, suggesting a potential upside of 144.25%. Given Chembio Diagnostics' higher probable upside, equities research analysts plainly believe Chembio Diagnostics is more favorable than Pieris Pharmaceuticals.

Chembio Diagnostics (NASDAQ:CEMI) and Trevena (NASDAQ:TRVN) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

Valuation & Earnings

This table compares Chembio Diagnostics and Trevena's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Chembio Diagnostics$32.47 million1.77$-25,520,000.00($1.28)-2.22
Trevena$3.07 million71.27$-29,370,000.00($0.23)-5.78

Chembio Diagnostics has higher revenue and earnings than Trevena. Trevena is trading at a lower price-to-earnings ratio than Chembio Diagnostics, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Chembio Diagnostics has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, Trevena has a beta of 2.44, suggesting that its share price is 144% more volatile than the S&P 500.

Institutional and Insider Ownership

34.0% of Chembio Diagnostics shares are held by institutional investors. Comparatively, 16.8% of Trevena shares are held by institutional investors. 3.8% of Chembio Diagnostics shares are held by company insiders. Comparatively, 2.7% of Trevena shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Chembio Diagnostics and Trevena's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Chembio Diagnostics-72.88%-79.63%-36.46%
TrevenaN/A-36.33%-30.78%

Analyst Ratings

This is a summary of current ratings and recommmendations for Chembio Diagnostics and Trevena, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Chembio Diagnostics01102.50
Trevena01302.75

Chembio Diagnostics presently has a consensus target price of $9.00, suggesting a potential upside of 216.90%. Trevena has a consensus target price of $5.00, suggesting a potential upside of 275.94%. Given Trevena's stronger consensus rating and higher probable upside, analysts plainly believe Trevena is more favorable than Chembio Diagnostics.

Summary

Trevena beats Chembio Diagnostics on 9 of the 14 factors compared between the two stocks.


Chembio Diagnostics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Sol-Gel Technologies logo
SLGL
Sol-Gel Technologies
1.7$11.23+0.2%$228.98 million$8.77 million-9.20Upcoming Earnings
Analyst Report
BELLUS Health logo
BLU
BELLUS Health
2.3$2.90+1.4%$227.19 million$10,000.00-5.47Analyst Upgrade
Short Interest Decrease
News Coverage
Kala Pharmaceuticals logo
KALA
Kala Pharmaceuticals
2.4$3.45+1.4%$223.01 million$6.36 million-1.76Upcoming Earnings
News Coverage
CTI BioPharma logo
CTIC
CTI BioPharma
1.8$2.37+0.8%$221.07 million$3.35 million-3.08Upcoming Earnings
Analyst Report
News Coverage
Pieris Pharmaceuticals logo
PIRS
Pieris Pharmaceuticals
1.8$3.48+1.7%$220.28 million$29.32 million-5.12Upcoming Earnings
News Coverage
Gap Down
Trevena logo
TRVN
Trevena
2.1$1.33+5.3%$218.80 million$3.07 million-5.54Gap Up
Spruce Biosciences logo
SPRB
Spruce Biosciences
2.2$9.21+3.3%$214.87 millionN/A-1.87
BCTG
BCTG Acquisition
0.3$10.02+0.8%$214.31 millionN/A0.00Short Interest Decrease
News Coverage
Galera Therapeutics logo
GRTX
Galera Therapeutics
2.5$8.38+4.5%$211.60 millionN/A-2.80Gap Up
Alpine Immune Sciences logo
ALPN
Alpine Immune Sciences
2.4$8.84+10.0%$211.45 million$9.34 million-5.78Analyst Downgrade
Positive News
Gap Up
TFF Pharmaceuticals logo
TFFP
TFF Pharmaceuticals
2.3$8.29+5.7%$210.23 millionN/A-8.05News Coverage
Positive News
Gap Up
Osmotica Pharmaceuticals logo
OSMT
Osmotica Pharmaceuticals
1.5$3.33+2.4%$208.39 million$177.88 million-2.40Short Interest Decrease
Checkpoint Therapeutics logo
CKPT
Checkpoint Therapeutics
1.6$2.63+1.1%$208.24 million$1.07 million-5.98Upcoming Earnings
Short Interest Increase
News Coverage
Xeris Pharmaceuticals logo
XERS
Xeris Pharmaceuticals
1.9$3.07+3.3%$203.73 million$20.16 million-1.82Upcoming Earnings
Short Interest Decrease
News Coverage
Gap Up
Atreca logo
BCEL
Atreca
2.4$5.49+10.6%$202.53 millionN/A-2.03Analyst Report
Unusual Options Activity
News Coverage
Gap Down
High Trading Volume
Hookipa Pharma logo
HOOK
Hookipa Pharma
1.8$7.73+1.6%$200.98 million$19.58 million-4.29
RPHM
Reneo Pharmaceuticals
2.2$8.19+3.3%$198.94 millionN/A0.00
Adamas Pharmaceuticals logo
ADMS
Adamas Pharmaceuticals
2.4$4.78+2.7%$197.75 million$74.46 million-2.67Upcoming Earnings
BioVie logo
BIVI
BioVie
1.8$14.14+6.4%$197.54 millionN/A-2.06Gap Up
Tyme Technologies logo
TYME
Tyme Technologies
1.2$1.14+2.6%$196.32 millionN/A-5.18
Jaguar Health logo
JAGX
Jaguar Health
2.0$1.40+4.3%$195.22 million$9.39 million0.00Analyst Revision
Gap Up
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
2.0$3.90+1.5%$192.54 million$3.38 million-5.06Upcoming Earnings
Short Interest Decrease
News Coverage
Lannett logo
LCI
Lannett
2.5$4.64+1.1%$192.33 million$545.74 million-0.94News Coverage
NextCure logo
NXTC
NextCure
2.2$6.93+1.2%$191.34 million$22.38 million-3.04Upcoming Earnings
Short Interest Increase
Immunome logo
IMNM
Immunome
2.0$16.22+0.4%$190.75 millionN/A-4.48
Terns Pharmaceuticals logo
TERN
Terns Pharmaceuticals
2.2$7.50+9.1%$188.33 millionN/A-0.07Lockup Expiration
News Coverage
Gap Up
Infinity Pharmaceuticals logo
INFI
Infinity Pharmaceuticals
1.8$2.12+9.9%$188.09 million$1.72 million-3.48Earnings Announcement
Analyst Report
Unusual Options Activity
Analyst Revision
Gap Up
Zynerba Pharmaceuticals logo
ZYNE
Zynerba Pharmaceuticals
1.6$4.41+2.7%$181.91 million$90,000.00-2.72News Coverage
Gap Up
Tricida logo
TCDA
Tricida
2.3$3.56+14.6%$178.96 millionN/A-0.73Short Interest Decrease
Gap Up
High Trading Volume
CMMB
Chemomab Therapeutics
1.9$16.63+1.1%$177.94 millionN/A-0.98News Coverage
Decibel Therapeutics logo
DBTX
Decibel Therapeutics
2.2$7.14+2.8%$177.79 millionN/A-0.36
AVEO Pharmaceuticals logo
AVEO
AVEO Pharmaceuticals
1.9$5.17+0.4%$177.64 million$6.02 million-2.59Upcoming Earnings
Analyst Downgrade
MediciNova logo
MNOV
MediciNova
1.9$3.63+2.2%$177.04 millionN/A-14.52Upcoming Earnings
Gap Up
Seelos Therapeutics logo
SEEL
Seelos Therapeutics
1.8$2.25+2.7%$176.81 million$380,000.00-3.88Short Interest Decrease
Adamis Pharmaceuticals logo
ADMP
Adamis Pharmaceuticals
1.7$1.18+10.2%$175.69 million$16.53 million-1.84Short Interest Increase
Gap Down
High Trading Volume
Gemini Therapeutics logo
GMTX
Gemini Therapeutics
2.4$4.07+7.6%$175.21 millionN/A0.00Gap Up
Mereo BioPharma Group logo
MREO
Mereo BioPharma Group
1.6$2.57+1.9%$174.22 millionN/A-0.83Short Interest Decrease
Gap Up
Ardelyx logo
ARDX
Ardelyx
2.4$1.74+1.7%$171.76 million$7.57 million-1.53Upcoming Earnings
Analyst Report
News Coverage
High Trading Volume
Biofrontera logo
BFRA
Biofrontera
0.9$6.05+4.0%$171.58 million$36.19 million-10.80Short Interest Decrease
Corbus Pharmaceuticals logo
CRBP
Corbus Pharmaceuticals
1.7$1.37+2.2%$171.29 million$3.94 million-1.15Upcoming Earnings
Gap Up
Aptinyx logo
APTX
Aptinyx
1.8$2.51+2.4%$171.11 million$1.56 million-2.70Short Interest Increase
Milestone Pharmaceuticals logo
MIST
Milestone Pharmaceuticals
1.9$5.70+4.0%$170.15 millionN/A-3.90Gap Down
ANEB
Anebulo Pharmaceuticals
1.7$7.26+1.9%$169.41 millionN/A0.00
Orphazyme A/S logo
ORPH
Orphazyme A/S
1.2$4.78+0.8%$167.06 millionN/A-1.40Short Interest Decrease
Marker Therapeutics logo
MRKR
Marker Therapeutics
2.0$2.09+1.4%$165.74 million$470,000.00-3.27Short Interest Decrease
Synlogic logo
SYBX
Synlogic
2.0$3.16+1.3%$165.49 million$550,000.00-2.04Upcoming Earnings
Analyst Downgrade
Satsuma Pharmaceuticals logo
STSA
Satsuma Pharmaceuticals
2.3$5.24+0.2%$165.22 millionN/A-2.06Short Interest Decrease
News Coverage
ContraFect logo
CFRX
ContraFect
2.1$4.12+1.0%$162.04 millionN/A-2.78
Strongbridge Biopharma logo
SBBP
Strongbridge Biopharma
1.6$2.39+3.8%$161.54 million$30.73 million-2.78Upcoming Earnings
Analyst Downgrade
Short Interest Decrease
News Coverage
Gap Up
Heat Biologics logo
HTBX
Heat Biologics
2.0$6.33+0.9%$160.78 million$2.95 million0.00Upcoming Earnings
Gap Down
This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.